- RA patients may benefit from weekly injection of Orencia, study finds
- Prasco agrees to distribute authorized generic of Pentasa
- As innovaters prep for patent cliff, generics prosper from patent losses
- Adherence among chronic disease patients can lead to big savings
- Pfizer forms licensing agreement with Seattle Genetics
NEW YORK — Drug maker Bristol-Myers Squibb will present 20 study abstracts at the American College of Rheumatology Annual Scientific Meeting in Chicago, the company said Thursday.
Bristol said that of those, 18 contain new data from studies of Orencia (abatacept) in patients with rheumatoid arthritis or lupus nephritis.
"The results presented at the American College of Rheumatology meeting reinforce Bristol-Myers Squibb's commitment to expanding our understanding of the efficacy and safety of Orencia and continuing to address the unmet needs of adult patients with moderate to severe rheumatoid arthritis," Bristol SVP global development and medical affairs Brian Daniels said.